Bio-Techne Corporation (TECH)
USD 52.69
(-3.96%)
USD 52.69
(-3.96%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 267.74 Million USD | -2.42% |
| 2023 | 274.39 Million USD | 78.87% |
| 2022 | 153.4 Million USD | -30.73% |
| 2021 | 221.46 Million USD | -22.81% |
| 2020 | 286.9 Million USD | -29.03% |
| 2019 | 404.27 Million USD | 86.29% |
| 2018 | 217.01 Million USD | -15.98% |
| 2017 | 258.29 Million USD | 271.52% |
| 2016 | 69.52 Million USD | 13.01% |
| 2015 | 61.51 Million USD | 120.13% |
| 2014 | -305.62 Million USD | -86.6% |
| 2013 | -163.78 Million USD | -40.38% |
| 2012 | -116.67 Million USD | -50.33% |
| 2011 | -77.61 Million USD | 21.54% |
| 2010 | -98.92 Million USD | 38.53% |
| 2009 | -160.94 Million USD | 3.62% |
| 2008 | -166.99 Million USD | -23.25% |
| 2007 | -135.48 Million USD | -77.79% |
| 2006 | -76.2 Million USD | -15.94% |
| 2005 | -65.72 Million USD | -85.97% |
| 2004 | -35.34 Million USD | -58.6% |
| 2003 | -22.28 Million USD | -167.14% |
| 2002 | -8.34 Million USD | -257.61% |
| 2001 | -2.33 Million USD | -197.07% |
| 2000 | 2.4 Million USD | 118.78% |
| 1999 | -12.8 Million USD | 53.28% |
| 1998 | -27.4 Million USD | -218.6% |
| 1997 | -8.6 Million USD | -16.22% |
| 1996 | -7.4 Million USD | -39.62% |
| 1995 | -5.3 Million USD | 10.17% |
| 1994 | -5.9 Million USD | -47.5% |
| 1993 | -4 Million USD | -66.67% |
| 1992 | -2.4 Million USD | -100.0% |
| 1991 | -1.2 Million USD | -500.0% |
| 1990 | -200 Thousand USD | 50.0% |
| 1989 | -400 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q4 | 267.74 Million USD | -24.54% |
| 2024 FY | 267.74 Million USD | -2.42% |
| 2024 Q2 | 425.56 Million USD | 6.16% |
| 2024 Q1 | 400.86 Million USD | 46.09% |
| 2024 Q3 | 354.81 Million USD | -16.63% |
| 2023 Q4 | 274.39 Million USD | -20.86% |
| 2023 FY | 274.39 Million USD | 78.87% |
| 2023 Q2 | 124.47 Million USD | -29.39% |
| 2023 Q3 | 346.7 Million USD | 178.53% |
| 2023 Q1 | 176.27 Million USD | 14.91% |
| 2022 Q2 | 139.8 Million USD | -22.75% |
| 2022 Q1 | 180.96 Million USD | -18.29% |
| 2022 FY | 153.4 Million USD | -30.73% |
| 2022 Q4 | 153.4 Million USD | -7.81% |
| 2022 Q3 | 166.4 Million USD | 19.03% |
| 2021 Q4 | 221.46 Million USD | 107.9% |
| 2021 Q1 | 229.62 Million USD | -19.96% |
| 2021 FY | 221.46 Million USD | -22.81% |
| 2021 Q2 | 139.59 Million USD | -39.21% |
| 2021 Q3 | 106.52 Million USD | -23.69% |
| 2020 Q4 | 286.9 Million USD | -16.27% |
| 2020 FY | 286.9 Million USD | -29.03% |
| 2020 Q2 | 353.75 Million USD | -24.46% |
| 2020 Q1 | 468.29 Million USD | 15.84% |
| 2020 Q3 | 342.66 Million USD | -3.13% |
| 2019 FY | 404.27 Million USD | 86.29% |
| 2019 Q2 | 459.48 Million USD | -1.57% |
| 2019 Q3 | 426.7 Million USD | -7.13% |
| 2019 Q1 | 466.79 Million USD | 115.1% |
| 2019 Q4 | 404.27 Million USD | -5.26% |
| 2018 Q2 | 241.04 Million USD | -9.05% |
| 2018 Q4 | 217.01 Million USD | -29.06% |
| 2018 Q1 | 265.03 Million USD | 2.61% |
| 2018 FY | 217.01 Million USD | -15.98% |
| 2018 Q3 | 305.89 Million USD | 26.9% |
| 2017 Q1 | 310.09 Million USD | 346.03% |
| 2017 Q2 | 288.31 Million USD | -7.02% |
| 2017 Q3 | 298.37 Million USD | 3.49% |
| 2017 Q4 | 258.29 Million USD | -13.43% |
| 2017 FY | 258.29 Million USD | 271.52% |
| 2016 Q4 | 69.52 Million USD | -27.51% |
| 2016 Q3 | 95.9 Million USD | -7.9% |
| 2016 Q2 | 104.12 Million USD | -12.79% |
| 2016 Q1 | 119.39 Million USD | 94.09% |
| 2016 FY | 69.52 Million USD | 13.01% |
| 2015 Q2 | 99.05 Million USD | 270.88% |
| 2015 FY | 61.51 Million USD | 120.13% |
| 2015 Q1 | 26.7 Million USD | 108.74% |
| 2015 Q3 | 83.56 Million USD | -15.63% |
| 2015 Q4 | 61.51 Million USD | -26.39% |
| 2014 Q4 | -305.62 Million USD | -147.26% |
| 2014 FY | -305.62 Million USD | -86.6% |
| 2014 Q1 | -83.85 Million USD | 48.8% |
| 2014 Q2 | -98.4 Million USD | -17.35% |
| 2014 Q3 | -123.6 Million USD | -25.61% |
| 2013 Q3 | -143.27 Million USD | 0.01% |
| 2013 Q2 | -143.28 Million USD | -9.54% |
| 2013 Q1 | -130.8 Million USD | -12.11% |
| 2013 FY | -163.78 Million USD | -40.38% |
| 2013 Q4 | -163.78 Million USD | -14.32% |
| 2012 Q4 | -116.67 Million USD | -22.45% |
| 2012 Q3 | -95.28 Million USD | -17.64% |
| 2012 Q2 | -80.99 Million USD | -2.22% |
| 2012 FY | -116.67 Million USD | -50.33% |
| 2012 Q1 | -79.23 Million USD | -2.09% |
| 2011 Q4 | -77.61 Million USD | 51.07% |
| 2011 Q1 | -115.01 Million USD | -22.17% |
| 2011 Q2 | -135.87 Million USD | -18.14% |
| 2011 Q3 | -158.62 Million USD | -16.75% |
| 2011 FY | -77.61 Million USD | 21.54% |
| 2010 Q4 | -94.13 Million USD | 13.02% |
| 2010 FY | -98.92 Million USD | 38.53% |
| 2010 Q3 | -108.23 Million USD | 44.65% |
| 2010 Q2 | -195.55 Million USD | -11.9% |
| 2010 Q1 | -174.75 Million USD | -8.59% |
| 2009 Q1 | -162.07 Million USD | 2.95% |
| 2009 Q4 | -160.94 Million USD | -20.27% |
| 2009 FY | -160.94 Million USD | 3.62% |
| 2009 Q3 | -133.82 Million USD | -11.9% |
| 2009 Q2 | -119.59 Million USD | 26.21% |
| 2008 Q2 | -148.65 Million USD | -2.7% |
| 2008 Q3 | -162.84 Million USD | -9.55% |
| 2008 FY | -166.99 Million USD | -23.25% |
| 2008 Q1 | -144.74 Million USD | -6.83% |
| 2008 Q4 | -166.99 Million USD | -2.54% |
| 2007 Q1 | -84.69 Million USD | -11.13% |
| 2007 Q2 | -102.55 Million USD | -21.1% |
| 2007 FY | -135.48 Million USD | -77.79% |
| 2007 Q3 | -116.27 Million USD | -13.38% |
| 2007 Q4 | -135.48 Million USD | -16.52% |
| 2006 Q2 | -54.71 Million USD | 12.04% |
| 2006 Q3 | -69.87 Million USD | -27.72% |
| 2006 Q4 | -76.2 Million USD | -9.06% |
| 2006 FY | -76.2 Million USD | -15.94% |
| 2006 Q1 | -62.2 Million USD | 5.37% |
| 2005 Q1 | -46.69 Million USD | -32.12% |
| 2005 FY | -65.72 Million USD | -85.97% |
| 2005 Q3 | -44.83 Million USD | 17.58% |
| 2005 Q2 | -54.39 Million USD | -16.49% |
| 2005 Q4 | -65.72 Million USD | -46.6% |
| 2004 FY | -35.34 Million USD | -58.6% |
| 2004 Q3 | -35.55 Million USD | -12.9% |
| 2004 Q2 | -31.49 Million USD | -15.63% |
| 2004 Q1 | -27.23 Million USD | -22.22% |
| 2004 Q4 | -35.34 Million USD | 0.6% |
| 2003 Q1 | -15.05 Million USD | -80.52% |
| 2003 FY | -22.28 Million USD | -167.14% |
| 2003 Q4 | -22.28 Million USD | -135.77% |
| 2003 Q3 | -9.45 Million USD | 15.88% |
| 2003 Q2 | -11.23 Million USD | 25.39% |
| 2002 Q2 | -11.58 Million USD | -319.64% |
| 2002 FY | -8.34 Million USD | -257.61% |
| 2002 Q4 | -8.34 Million USD | -6.04% |
| 2002 Q3 | -7.86 Million USD | 32.07% |
| 2002 Q1 | -2.75 Million USD | -18.31% |
| 2001 Q4 | -2.33 Million USD | -546.89% |
| 2001 Q3 | 521.99 Thousand USD | -79.13% |
| 2001 Q1 | -1.69 Million USD | -170.57% |
| 2001 Q2 | 2.5 Million USD | 247.47% |
| 2001 FY | -2.33 Million USD | -197.07% |
| 2000 Q3 | 1.79 Million USD | 28.24% |
| 2000 Q1 | 6.3 Million USD | 149.22% |
| 2000 FY | 2.4 Million USD | 118.78% |
| 2000 Q4 | 2.4 Million USD | 33.86% |
| 2000 Q2 | 1.4 Million USD | -77.78% |
| 1999 Q3 | -11.3 Million USD | 17.52% |
| 1999 Q4 | -12.8 Million USD | -13.27% |
| 1999 Q2 | -13.7 Million USD | -29.25% |
| 1999 Q1 | -10.6 Million USD | 61.31% |
| 1999 FY | -12.8 Million USD | 53.28% |
| 1998 Q4 | -27.4 Million USD | -126.45% |
| 1998 Q3 | -12.1 Million USD | -22.22% |
| 1998 Q2 | -9.9 Million USD | -8.79% |
| 1998 FY | -27.4 Million USD | -218.6% |
| 1998 Q1 | -9.1 Million USD | -5.81% |
| 1997 Q2 | -7 Million USD | -25.0% |
| 1997 FY | -8.6 Million USD | -16.22% |
| 1997 Q4 | -8.6 Million USD | -59.26% |
| 1997 Q1 | -5.6 Million USD | 24.32% |
| 1997 Q3 | -5.4 Million USD | 22.86% |
| 1996 Q4 | -7.4 Million USD | -29.82% |
| 1996 FY | -7.4 Million USD | -39.62% |
| 1996 Q3 | -5.7 Million USD | -39.02% |
| 1996 Q2 | -4.1 Million USD | 31.67% |
| 1996 Q1 | -6 Million USD | -13.21% |
| 1995 Q1 | -6 Million USD | -1.69% |
| 1995 FY | -5.3 Million USD | 10.17% |
| 1995 Q4 | -5.3 Million USD | -1.92% |
| 1995 Q3 | -5.2 Million USD | -15.56% |
| 1995 Q2 | -4.5 Million USD | 25.0% |
| 1994 Q4 | -5.9 Million USD | -15.69% |
| 1994 Q1 | -3.4 Million USD | 15.0% |
| 1994 Q2 | -3.4 Million USD | 0.0% |
| 1994 Q3 | -5.1 Million USD | -50.0% |
| 1994 FY | -5.9 Million USD | -47.5% |
| 1993 FY | -4 Million USD | -66.67% |
| 1993 Q2 | -2 Million USD | -400.0% |
| 1993 Q3 | -2.5 Million USD | -25.0% |
| 1993 Q4 | -4 Million USD | -60.0% |
| 1993 Q1 | -400 Thousand USD | 83.33% |
| 1992 Q4 | -2.4 Million USD | -71.43% |
| 1992 FY | -2.4 Million USD | -100.0% |
| 1992 Q1 | 1 Million USD | 183.33% |
| 1992 Q2 | 400 Thousand USD | -60.0% |
| 1992 Q3 | -1.4 Million USD | -450.0% |
| 1991 Q4 | -1.2 Million USD | -200.0% |
| 1991 Q3 | -400 Thousand USD | 20.0% |
| 1991 Q2 | -500 Thousand USD | 54.55% |
| 1991 Q1 | -1.1 Million USD | -450.0% |
| 1991 FY | -1.2 Million USD | -500.0% |
| 1990 FY | -200 Thousand USD | 50.0% |
| 1990 Q4 | -200 Thousand USD | 0.0% |
| 1990 Q3 | -200 Thousand USD | -150.0% |
| 1990 Q2 | 400 Thousand USD | 500.0% |
| 1990 Q1 | -100 Thousand USD | 0.0% |
| 1989 FY | -400 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 578.632% |
| Alkermes plc | -166.73 Million USD | 260.579% |
| Agenus Inc. | 274.13 Million USD | 2.331% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 85.682% |
| Aptorum Group Limited | 1.35 Million USD | -19630.134% |
| Ardelyx, Inc. | 34.51 Million USD | -675.808% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | -6155.771% |
| Bicycle Therapeutics plc | -481.46 Million USD | 155.611% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | -640.389% |
| ChromaDex Corporation | -24.04 Million USD | 1213.386% |
| Chimerix, Inc. | -25.51 Million USD | 1149.289% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -3742.481% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 1230.832% |
| CRISPR Therapeutics AG | -150.84 Million USD | 277.498% |
| Precision BioSciences, Inc. | -85.41 Million USD | 413.484% |
| Dyadic International, Inc. | -6.37 Million USD | 4297.912% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 1780.456% |
| Fortress Biotech, Inc. | 7.66 Million USD | -3393.112% |
| Lantern Pharma Inc. | -21.7 Million USD | 1333.671% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 342.224% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 3234.045% |
| Incyte Corporation | -3.17 Billion USD | 108.433% |
| IO Biotech, Inc. | -140.69 Million USD | 290.298% |
| Jaguar Health, Inc. | 29.39 Million USD | -810.983% |
| Novavax, Inc. | -298.29 Million USD | 189.759% |
| Janux Therapeutics, Inc. | 5.33 Million USD | -4916.807% |
| Opthea Limited | 28.15 Million USD | -850.892% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 1694.776% |
| ContextLogic Inc. | -232 Million USD | 215.408% |
| MiMedx Group, Inc. | -33.9 Million USD | 889.791% |
| Pyxis Oncology, Inc. | 10.19 Million USD | -2526.258% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 11655.627% |
| NextCure, Inc. | -6.47 Million USD | 4233.812% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 630.182% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 4297.319% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | -2101.275% |
| Vaxcyte, Inc. | -368.22 Million USD | 172.712% |
| PDS Biotechnology Corporation | -32.7 Million USD | 918.575% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | -1449.641% |
| Pharming Group N.V. | 109.8 Million USD | -143.841% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 1639.13% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 252.797% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 1545.729% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 1545.729% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 3871.085% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 4669.061% |
| Acelyrin, Inc. | -216.9 Million USD | 223.441% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 4872.447% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 15630.568% |
| Summit Therapeutics Inc. | 34.67 Million USD | -672.184% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 4035.72% |
| Senti Biosciences, Inc. | 1.74 Million USD | -15287.759% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 245.036% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 445.699% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 4516.81% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -268266.928% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -42534.873% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 328.754% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 259.152% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | -141.496% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 3624.842% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 307.373% |
| Psyence Biomedical Ltd. | 6.89 Million USD | -3783.432% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 210.474% |
| Immix Biopharma, Inc. | -17.5 Million USD | 1629.127% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 184.542% |
| MEI Pharma, Inc. | -3.7 Million USD | 7326.64% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | -2040.093% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | -65.54% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | -863.361% |
| Fortress Biotech, Inc. | 7.66 Million USD | -3393.112% |
| Precigen, Inc. | -481 Thousand USD | 55764.657% |
| Clearside Biomedical, Inc. | 14.08 Million USD | -1801.477% |
| AlloVir, Inc. | -62.69 Million USD | 527.083% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 581.438% |
| Fate Therapeutics, Inc. | 61.66 Million USD | -334.189% |
| ImmuCell Corporation | 10.99 Million USD | -2336.154% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 273.697% |
| Onconetix, Inc. | 5.33 Million USD | -4922.042% |
| PureTech Health plc | -167.19 Million USD | 260.139% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 979.012% |
| Elevation Oncology, Inc. | -19.11 Million USD | 1500.497% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 5554.207% |
| Seer, Inc. | -4.24 Million USD | 6414.788% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 1213.895% |
| Innoviva, Inc. | 255.56 Million USD | -4.768% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 579.284% |
| ESSA Pharma Inc. | -33.62 Million USD | 896.355% |
| GlycoMimetics, Inc. | -40.98 Million USD | 753.29% |
| GT Biopharma, Inc. | -1.02 Million USD | 26323.996% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 495.006% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | -337.088% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 299.693% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 2032.354% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 1027.359% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 355513.226% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 967.562% |
| Aptose Biosciences Inc. | -8.19 Million USD | 3367.257% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 8656.902% |
| Soligenix, Inc. | -4.95 Million USD | 5507.286% |
| Century Therapeutics, Inc. | 847 Thousand USD | -31511.216% |
| Kura Oncology, Inc. | -20.11 Million USD | 1430.883% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 754.222% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 3288.223% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -14597.685% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 8474.945% |
| Autolus Therapeutics plc | -186.59 Million USD | 243.488% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 643.053% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 197.082% |
| Eterna Therapeutics Inc. | 34.26 Million USD | -681.332% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | -62.895% |
| GRI Bio, Inc. | -1.79 Million USD | 15024.582% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 3080.581% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 905.085% |
| IGM Biosciences, Inc. | -72.6 Million USD | 468.767% |
| INmune Bio, Inc. | -25.41 Million USD | 1153.666% |
| Heron Therapeutics, Inc. | 150.95 Million USD | -77.373% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 628.528% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 1747.738% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 9380.897% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | -604.319% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 750.108% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -739.727% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 29.158% |
| Verastem, Inc. | -37.27 Million USD | 818.244% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 3051.031% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 616.268% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 1869.058% |
| Histogen Inc. | -7.48 Million USD | 3676.159% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 1339.178% |
| Surrozen, Inc. | -32.66 Million USD | 919.701% |
| Organovo Holdings, Inc. | -1.5 Million USD | 17866.888% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 6469.639% |
| Ovid Therapeutics Inc. | 18.96 Million USD | -1312.152% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -10134.977% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | -6342.421% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 3294.633% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 716.332% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 1936.795% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 184.519% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 37180.99% |
| Apollomics, Inc. | -27.39 Million USD | 1077.357% |
| Amarin Corporation plc | -191.04 Million USD | 240.152% |
| Mesoblast Limited | 55.96 Million USD | -378.436% |
| Turnstone Biologics Corp. | -14.58 Million USD | 1935.896% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 1158.623% |
| Synaptogenix, Inc. | -28.66 Million USD | 1034.17% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 28705.449% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | -449.427% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 31157.93% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 3784.889% |
| Exelixis, Inc. | -73.05 Million USD | 466.526% |
| Better Therapeutics, Inc. | -860 Thousand USD | 31233.372% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 1215.009% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 210.928% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -36275.407% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 3699.652% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -21251.435% |
| Gritstone bio, Inc. | 39.49 Million USD | -578.012% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 418.364% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 10272.217% |
| Avid Bioservices, Inc. | 169.72 Million USD | -57.751% |
| Insmed Incorporated | 721.62 Million USD | 62.896% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 3028.914% |
| MediWound Ltd. | -5.32 Million USD | 5130.947% |
| OmniAb, Inc. | 9.2 Million USD | -2809.345% |
| Alector, Inc. | -35.63 Million USD | 851.317% |
| Seres Therapeutics, Inc. | 85.97 Million USD | -211.439% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 5533.178% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | -1922.411% |
| Zai Lab Limited | -775 Million USD | 134.548% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 21.379% |
| Aura Biosciences, Inc. | -21.52 Million USD | 1343.889% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 424.621% |
| Immunic, Inc. | -45.34 Million USD | 690.532% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 238.575% |
| Veracyte, Inc. | -203.82 Million USD | 231.362% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 58.053% |
| FibroGen, Inc. | 56.76 Million USD | -371.66% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -2906.704% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 9570.79% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 13032.464% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 94.167% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 8113.978% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 261.328% |
| TG Therapeutics, Inc. | 17.86 Million USD | -1398.975% |
| Galecto, Inc. | -21.21 Million USD | 1362.005% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 1225.697% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 82.94% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 1194.095% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 2426.818% |
| XBiotech Inc. | -200.02 Million USD | 233.858% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 418.364% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | -5813.14% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 859.286% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 446.742% |
| Theravance Biopharma, Inc. | 5.69 Million USD | -4604.744% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 257.115% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 389.851% |
| Vaxxinity, Inc. | 10.13 Million USD | -2542.588% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 63.634% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 2586.61% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 505.948% |
| NexImmune, Inc. | -3.13 Million USD | 8644.273% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 7854.774% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 1871.815% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 1087.996% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 3082.904% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 215028.356% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 759.93% |
| Ainos, Inc. | 4.07 Million USD | -6465.761% |
| Pluri Inc. | 22.82 Million USD | -1072.837% |
| Prothena Corporation plc | -608.34 Million USD | 144.012% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 325.46% |
| Celularity Inc. | 65.19 Million USD | -310.718% |
| Rallybio Corporation | -24.1 Million USD | 1210.891% |
| Cue Biopharma, Inc. | -33.81 Million USD | 891.706% |
| MeiraGTx Holdings plc | -40.3 Million USD | 764.352% |
| Omeros Corporation | 331.17 Million USD | 19.153% |
| Humacyte, Inc. | -22.48 Million USD | 1290.728% |
| Immunocore Holdings plc | -358.59 Million USD | 174.666% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 1189.51% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 966.467% |
| Blueprint Medicines Corporation | 702.83 Million USD | 61.905% |
| CalciMedica, Inc. | -5.53 Million USD | 4941.718% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 242.252% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 2721.373% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 768.749% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 905.181% |
| Pulmatrix, Inc. | -10.41 Million USD | 2670.289% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 4579.622% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 801.974% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 340.343% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 546.662% |
| Cytokinetics, Incorporated | 642.37 Million USD | 58.319% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 4698.094% |
| Nutriband Inc. | -251.65 Thousand USD | 106493.623% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 884.745% |
| Vor Biopharma Inc. | 4.3 Million USD | -6126.674% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 104.436% |
| Evogene Ltd. | -19.63 Million USD | 1463.691% |
| ProKidney Corp. | -56.23 Million USD | 576.113% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 650.105% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 2998.577% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 80.369% |
| CorMedix Inc. | -43.05 Million USD | 721.908% |
| BioLineRx Ltd. | 7.33 Million USD | -3549.768% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 1074.866% |
| Galectin Therapeutics Inc. | 46.14 Million USD | -480.205% |
| Atai Life Sciences N.V. | -28.55 Million USD | 1037.555% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -11903.744% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 1273.505% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | -1409.71% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 456.644% |
| MediciNova, Inc. | -50.78 Million USD | 627.232% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 439.759% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 1190351.167% |
| GeoVax Labs, Inc. | -6.45 Million USD | 4249.451% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 233.993% |
| Biomea Fusion, Inc. | -166.57 Million USD | 260.741% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 249.6% |
| Mereo BioPharma Group plc | -51.46 Million USD | 620.21% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 382.303% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 191.145% |
| Absci Corporation | -72.59 Million USD | 468.808% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -5763.929% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 214.209% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 384.199% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 379.789% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 785.248% |
| Allakos Inc. | -24.97 Million USD | 1172.06% |
| Imunon, Inc. | -4.21 Million USD | 6453.973% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 1916.219% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 297.745% |
| BioAtla, Inc. | -109.01 Million USD | 345.615% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -36275.407% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 28614.058% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | -2137.565% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 1362.779% |
| XOMA Corporation | -29 Million USD | 1023.266% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 1716.83% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 3069.687% |
| aTyr Pharma, Inc. | -7.44 Million USD | 3694.402% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 314.823% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 228.623% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 427.403% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 388.636% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 31262.941% |
| Akari Therapeutics, Plc | -3.84 Million USD | 7063.511% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -16398.161% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 80.61% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 22635.065% |
| UroGen Pharma Ltd. | 4.39 Million USD | -5997.632% |
| Sutro Biopharma, Inc. | 113.48 Million USD | -135.94% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -371967.202% |
| Orgenesis Inc. | 21.78 Million USD | -1129.099% |
| Entera Bio Ltd. | -10.62 Million USD | 2619.023% |
| GH Research PLC | -78.07 Million USD | 442.927% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 1301.306% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 1104.34% |
| Xencor, Inc. | 29.64 Million USD | -803.208% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 13692.515% |
| Replimune Group, Inc. | 1.41 Million USD | -18862.252% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 109425.543% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 311.797% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 22635.065% |
| Portage Biotech Inc. | -4.98 Million USD | 5475.366% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 1190351.167% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 504.929% |
| OncoCyte Corporation | -6.56 Million USD | 4179.643% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -29735.427% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 5977.26% |
| Purple Biotech Ltd. | -14.13 Million USD | 1993.811% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 1227.071% |
| scPharmaceuticals Inc. | -6.54 Million USD | 4190.863% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 1704.028% |
| HilleVax, Inc. | -165.48 Million USD | 261.795% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 10649.527% |
| Tharimmune, Inc. | -10.93 Million USD | 2548.453% |
| Genprex, Inc. | -6.73 Million USD | 4073.905% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 172.598% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 402.676% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 19211.135% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 8172.094% |
| OKYO Pharma Limited | -826.84 Thousand USD | 32481.647% |
| Savara Inc. | 153 Thousand USD | -174898.039% |
| Curis, Inc. | -23.88 Million USD | 1220.89% |
| Daré Bioscience, Inc. | -5.15 Million USD | 5290.997% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 34602.946% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 4412.935% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -22494.684% |
| BeiGene, Ltd. | -2.25 Billion USD | 111.884% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | -2070.013% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 144.023% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 244.271% |
| Erasca, Inc. | -37.21 Million USD | 819.441% |
| bluebird bio, Inc. | 108.57 Million USD | -146.61% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 20889.538% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 29.307% |
| DBV Technologies S.A. | -126.98 Million USD | 310.848% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 20889.538% |
| Moderna, Inc. | -2.9 Billion USD | 109.21% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 2686.428% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 2563.627% |
| Molecular Templates, Inc. | 707 Thousand USD | -37770.863% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 953.486% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 22.752% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 426.274% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 391.886% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 929.657% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 878.878% |
| MacroGenics, Inc. | -66.98 Million USD | 499.712% |
| RenovoRx, Inc. | -1.17 Million USD | 22925.831% |
| Adicet Bio, Inc. | -138.78 Million USD | 292.919% |
| Prime Medicine, Inc. | -27.94 Million USD | 1058.258% |
| Aditxt, Inc. | 18.12 Million USD | -1377.56% |
| Adagene Inc. | -87.62 Million USD | 405.552% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 6527.839% |
| Quantum-Si incorporated | -118.55 Million USD | 325.838% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | -643.638% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 3682.289% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 651.953% |
| SciSparc Ltd. | -2.06 Million USD | 13065.956% |
| Vericel Corporation | 1.27 Million USD | -20866.875% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 2332.769% |
| Minerva Neurosciences, Inc. | 41 Million USD | -552.974% |
| Generation Bio Co. | 31.44 Million USD | -751.396% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 252.681% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 965.851% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | -129.642% |
| Invivyd, Inc. | -198.47 Million USD | 234.901% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 396.607% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 11266.881% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 478.227% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 4023.033% |
| 2seventy bio, Inc. | 181.71 Million USD | -47.344% |
| ADMA Biologics, Inc. | 90.06 Million USD | -197.279% |
| Clene Inc. | 3.34 Million USD | -7916.377% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 3047.878% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 1344.698% |
| GeoVax Labs, Inc. | -6.45 Million USD | 4249.451% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 177.805% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 1129.809% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | -50.702% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 6643.874% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -5252.799% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 5240.084% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 305.479% |
| Evaxion Biotech A/S | 5.28 Million USD | -4964.401% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 337.854% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 303.962% |
| Trevena, Inc. | 2.25 Million USD | -11757.706% |
| Surrozen, Inc. | -32.66 Million USD | 919.701% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 619.796% |
| Cingulate Inc. | 3.08 Million USD | -8585.518% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 9216.343% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -3625.435% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 2981.718% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 437.54% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 303.684% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 353.688% |
| Clearmind Medicine Inc. | -3.94 Million USD | 6891.064% |
| Kronos Bio, Inc. | -36.05 Million USD | 842.628% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | -2745.648% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -18262.392% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 593.488% |
| Statera Biopharma, Inc. | 14.41 Million USD | -1757.238% |
| ImmunityBio, Inc. | 618.22 Million USD | 56.691% |
| Korro Bio, Inc. | -132.94 Million USD | 301.4% |
| Kineta, Inc. | -4.54 Million USD | 5996.212% |
| BioVie Inc. | -17.73 Million USD | 1609.935% |
| Codexis, Inc. | -43.27 Million USD | 718.768% |
| Celularity Inc. | 65.19 Million USD | -310.718% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 8548.943% |
| Celcuity Inc. | 6.78 Million USD | -3847.028% |
| Virax Biolabs Group Limited | -3.36 Million USD | 8056.953% |
| Cibus, Inc. | -8.07 Million USD | 3414.521% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 6431.213% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -5758.796% |
| IN8bio, Inc. | -16.38 Million USD | 1733.699% |
| Kodiak Sciences Inc. | -103.87 Million USD | 357.759% |
| Annexon, Inc. | -193.75 Million USD | 238.188% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -743641.667% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 1630.07% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 7721.605% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 74.604% |
| Eyenovia, Inc. | 1.25 Million USD | -21171.675% |
| Puma Biotechnology, Inc. | 26.9 Million USD | -895.157% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 8356.152% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 905.327% |
| Arcellx, Inc. | -296.95 Million USD | 190.163% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 1472.639% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 554.772% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 1391.779% |
| Moolec Science SA | 117.61 Thousand USD | -227545.048% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 797.276% |
| Geron Corporation | 14.76 Million USD | -1713.881% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 806.121% |
| Royalty Pharma plc | 5.65 Billion USD | 95.268% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 289.326% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 3930.745% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 5092.617% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 290.254% |
| Humacyte, Inc. | -22.48 Million USD | 1290.728% |
| Structure Therapeutics Inc. | -124.33 Million USD | 315.336% |
| 89bio, Inc. | -289.05 Million USD | 192.629% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 1160.72% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 15116.657% |
| Genelux Corporation | -6.89 Million USD | 3980.954% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 962.059% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | -220.275% |
| Notable Labs, Ltd. | -9.77 Million USD | 2838.82% |
| Liquidia Corporation | -80.17 Million USD | 433.949% |
| Mustang Bio, Inc. | -3.73 Million USD | 7266.676% |
| Immunovant, Inc. | -635.22 Million USD | 142.15% |
| Quantum-Si incorporated | -118.55 Million USD | 325.838% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 1624.408% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 6562.636% |
| Vera Therapeutics, Inc. | 8.02 Million USD | -3235.58% |
| Acasti Pharma Inc. | -23 Million USD | 1263.864% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 8051.553% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 1747.738% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 294.386% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 8691.653% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 1304.332% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 1541.903% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 258.17% |
| PepGen Inc. | -60.67 Million USD | 541.317% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 1265.333% |
| United Therapeutics Corporation | -507.7 Million USD | 152.737% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 1499.911% |
| Solid Biosciences Inc. | -47.75 Million USD | 660.727% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 31157.93% |
| Immuneering Corporation | -54.94 Million USD | 587.319% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 6469.639% |
| Silo Pharma, Inc. | -3.52 Million USD | 7697.151% |
| Belite Bio, Inc | -87.27 Million USD | 406.8% |
| XOMA Corporation | -29 Million USD | 1023.266% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 478.725% |
| Bionomics Limited | 227 Million USD | -17.945% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 330.257% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 10670.351% |
| uniQure N.V. | -102.95 Million USD | 360.072% |
| Cassava Sciences, Inc. | -121.13 Million USD | 321.03% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 6527.839% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | -553.823% |
| Forte Biosciences, Inc. | -11.96 Million USD | 2338.5% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 8753.19% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -252491.509% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 8356.152% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -2906.704% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 3710.396% |
| Altimmune, Inc. | -134.48 Million USD | 299.088% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -35.181% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 10670.351% |
| Compugen Ltd. | -12.9 Million USD | 2174.915% |
| Peak Bio, Inc. | 10.34 Million USD | -2489.39% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 94710.247% |
| Benitec Biopharma Inc. | -50.58 Million USD | 629.333% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 356.615% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | -1262.927% |
| Zura Bio Limited | -99.8 Million USD | 368.267% |
| PolyPid Ltd. | 6.17 Million USD | -4239.498% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | -261.234% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | -1262.927% |
| Instil Bio, Inc. | 75.35 Million USD | -255.3% |
| argenx SE | -2.02 Billion USD | 113.197% |
| Immunome, Inc. | -97.02 Million USD | 375.945% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 1290.251% |
| Verona Pharma plc | -220.44 Million USD | 221.459% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 473.203% |
| Shattuck Labs, Inc. | -121.42 Million USD | 320.506% |
| CervoMed Inc. | -7.79 Million USD | 3535.805% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 244.339% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 6222.73% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 303.239% |
| Moolec Science SA | 117.61 Thousand USD | -227545.048% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 11802.347% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | -1584.115% |
| AnaptysBio, Inc. | -18.15 Million USD | 1575.109% |
| Design Therapeutics, Inc. | -18.15 Million USD | 1575.19% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 480.425% |
| NeurAxis, Inc. | 145.7 Thousand USD | -183665.957% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | -2283.787% |
| Lumos Pharma, Inc. | -28.49 Million USD | 1039.694% |
| Achilles Therapeutics plc | -126.92 Million USD | 310.951% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 473.203% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 40931.897% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 1388.867% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -18262.392% |
| Nutriband Inc. | -251.65 Thousand USD | 106493.623% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 2132.852% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 3698.75% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 21.296% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | -1028.068% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 159.836% |
| Palisade Bio, Inc. | -12.06 Million USD | 2319.572% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 290.824% |
| Beam Therapeutics Inc. | -262.72 Million USD | 201.913% |
| Neurogene Inc. | -131.95 Million USD | 302.908% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | -1127.296% |
| AEON Biopharma, Inc. | -4.88 Million USD | 5586.619% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 170.984% |
| Sesen Bio, Inc. | -112.55 Million USD | 337.885% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 368.122% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 11504.2% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 786.073% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 421.494% |
| Athira Pharma, Inc. | -88.99 Million USD | 400.843% |
| Vaccinex, Inc. | -1.28 Million USD | 20887.811% |
| HCW Biologics Inc. | 2.85 Million USD | -9272.676% |
| XOMA Corporation | -29 Million USD | 1023.266% |
| Nektar Therapeutics | 210.24 Million USD | -27.353% |
| Arvinas, Inc. | -313.8 Million USD | 185.324% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -16398.161% |
| Merus N.V. | -192.88 Million USD | 238.812% |
| Omega Therapeutics, Inc. | 59.98 Million USD | -346.357% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 3959.138% |
| Rezolute, Inc. | -68.16 Million USD | 492.775% |
| Clene Inc. | 3.34 Million USD | -7916.377% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 2130.386% |
| BeyondSpring Inc. | -13.75 Million USD | 2046.543% |
| Synlogic, Inc. | -6.68 Million USD | 4105.191% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -23510.847% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 3266.73% |
| Peak Bio, Inc. | 10.34 Million USD | -2489.39% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 424.857% |
| Krystal Biotech, Inc. | -350.23 Million USD | 176.448% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | -115.708% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 258.434% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 8580.671% |
| MannKind Corporation | 143.89 Million USD | -86.066% |
| Ikena Oncology, Inc. | -109.15 Million USD | 345.288% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 3636.481% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 908.903% |
| Gossamer Bio, Inc. | 180.35 Million USD | -48.456% |
| CohBar, Inc. | -5.93 Million USD | 4614.57% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 1000.05% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -5763.929% |
| Legend Biotech Corporation | -949.39 Million USD | 128.202% |
| Mural Oncology plc | -255.84 Million USD | 204.653% |
| Biora Therapeutics, Inc. | 32.21 Million USD | -731.125% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 5783.875% |
| Disc Medicine, Inc. | -358.28 Million USD | 174.731% |
| Champions Oncology, Inc. | 4.81 Million USD | -5464.152% |
| REGENXBIO Inc. | 54.76 Million USD | -388.875% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 99668.624% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 277.288% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 3071.003% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 431.851% |
| Vaxart, Inc. | -8.24 Million USD | 3348.963% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 633.573% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 310.55% |
| Cellectis S.A. | -43.85 Million USD | 710.528% |
| Longeveron Inc. | -2.9 Million USD | 9307.256% |
| Repare Therapeutics Inc. | -107.85 Million USD | 348.24% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 72.351% |
| Inozyme Pharma, Inc. | 12 Million USD | -2130.482% |
| Revolution Medicines, Inc. | -608.2 Million USD | 144.023% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 21868.049% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 200.992% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 278.412% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 1811.171% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 36282.027% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 102.8% |
| Denali Therapeutics Inc. | -74.86 Million USD | 457.64% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 2332.769% |
| Veru Inc. | 4.77 Million USD | -5501.438% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 2480.82% |
| Cingulate Inc. | 3.08 Million USD | -8585.518% |
| Passage Bio, Inc. | 4.58 Million USD | -5739.629% |
| Context Therapeutics Inc. | -14.44 Million USD | 1952.943% |
| Exicure, Inc. | 5.84 Million USD | -4477.654% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 216.222% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 776.641% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | -1606.373% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 555.189% |
| Nuvalent, Inc. | -335.38 Million USD | 179.832% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -15337.968% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 459.479% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 3111.777% |
| OmniAb, Inc. | 9.2 Million USD | -2809.345% |
| Anew Medical, Inc. | 1.43 Million USD | -18591.347% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | -1534.422% |
| Lipocine Inc. | -4.75 Million USD | 5731.335% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 343.788% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | -1657.908% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 628.528% |
| G1 Therapeutics, Inc. | 24.89 Million USD | -975.635% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 4083.738% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 506.743% |
| Ocugen, Inc. | -32.52 Million USD | 923.305% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 412.88% |
| Q32 Bio Inc. | -37.94 Million USD | 805.563% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 42734.873% |
| Alumis Inc. Common Stock | -13.52 Million USD | 2079.06% |
| Equillium, Inc. | -22.39 Million USD | 1295.726% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 1147.196% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 920.636% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 108099.516% |
| Galera Therapeutics, Inc. | 134.04 Million USD | -99.749% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -8272.326% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -81420.578% |
| Dominari Holdings Inc. | 195 Thousand USD | -137206.154% |
| Edesa Biotech, Inc. | -5.26 Million USD | 5183.569% |
| vTv Therapeutics Inc. | -8.91 Million USD | 3102.658% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 1751.842% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 326.724% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 3286.326% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 2216.41% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 209.231% |
| Nkarta, Inc. | 57.29 Million USD | -367.28% |
| BioCardia, Inc. | 212 Thousand USD | -126195.755% |
| Iterum Therapeutics plc | 13.43 Million USD | -1892.462% |